Brief: NKGen Biotech Receives Deficiency Letter From Nasdaq
27/09/2024 21:12
Sept 27 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH INC -ON SEPT 23, GOT DEFICIENCY LETTER FROM
NASDAQ ON CO'S FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD
Source text for Eikon: ID:n0001213900-24-082695
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program